Showing 1,441 - 1,460 results of 45,258 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (mean decrease)) ))', query time: 1.23s Refine Results
  1. 1441
  2. 1442
  3. 1443
  4. 1444
  5. 1445

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  6. 1446

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  7. 1447

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  8. 1448

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  9. 1449

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  10. 1450
  11. 1451

    The effects of TDBP-TAZTO (5 and 50 mg/kg) on spatial learning and memory in rats in the Morris water test. by Liang Ye (6646)

    Published 2015
    “…Data ate expressed as mean ± SE (n = 10/group). <sup>a</sup><i>p</i> < 0.05, TDBP-TAZTO 5 mg/kg group vs. control group; <sup>b</sup><i>p</i> < 0.05, TDBP-TAZTO 50 mg/kg group vs. control group.…”
  12. 1452
  13. 1453
  14. 1454
  15. 1455
  16. 1456
  17. 1457

    Effects of siRNA TMPRSS2-ERG on ERG protein expression and cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 24h, 48h and 72h with 50 nM of siRNAs TMPRSS2-ERG III (1, 2, 3), siRNAs TMPRSS2-ERG IV (1, 2), siRNA against ERG wild type or siRNA Control. …”
  18. 1458
  19. 1459
  20. 1460